Enterome's innovative OncoMimics™-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma

Corporate Breaking News

Home : Enterome's innovative OncoMimics™-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma

Sep 16 2022	Enterome's innovative OncoMimics™-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma
PARIS, Sept. 16, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that an oral presentation of its Phase 1/2 clinical trial of EO2401 in...


Source:https://www.prnewswire.com:443/news-releases/enteromes-innovative-oncomimics-based-immunotherapy-eo2401-distinguished-with-best-clinical-research-award-at-eano-meeting-2022-for-promising-results-in-recurrent-gliobastoma-301626054.html

Related News
» El primer ministro se reúne con los principales estudios cinematográficos para discutir el desarrollo de la industria cinematográfica mongola » Atlas obtiene de Sixth Street Growth una inversión estratégica de la serie B de hasta 200 millones de USD